Owen Catherine E.
Known title: DirectorCIK: 0001816838
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
Transaction History
| AGIO | ▲ Buy | Option Exercise | 2,816 | $0 | 6/18/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 1,976 | $0 | 6/13/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 11,641 | $250K | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 23,509 | $0 | 3/24/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,120 | $0 | 6/20/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 1,977 | $0 | 6/13/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 1,976 | $0 | 6/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call
AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.